|
|
Blood, Vol. 109, Issue 12, 5511-5519, June 15, 2007
Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Blood Weissinger et al.
109: 5511
Supplemental materials for: Weissinger et al, Vol 109, Issue 12, 5511-5519
Files in this Data Supplement:
- Table S1. Summary of the clinical data of the patients after HSCT (XLS, 33 KB)
-
For all patients in this study, the patient_ID, the age in years, the initial diagnosis, the type of stem cell transplantation (Type of HSCT), the conditioning regime used, the source of transplanted cells, the day of aGvHD diagnosis (in days after HSCT), and the grade of GvHD are shown.
Abbreviations:
Diagnosis. AML indicates acute myelogenous leukemia; sAML, secondary acute myelogenous leukemial; ALL, acute lymphoblastic leukemia; PLL, prolymphocytic leukemia; SLL, small lymphocytic lymphoma; CML, chronic myelogenous leukemia; CLL, chronic lymphoblastic leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; HD, Hodgkin disease; NHL, nonHodgkin lymphoma; NK-T-lymphoma, Natural Killer T-cell lymphoma; OMF, osteomyelofibrosis; sAA, (very) severe aplastic anemia; PNH, paroxysmal nocturnal hematuria; Type of HSCT. Haplo indicates haploidentical; MUD, matched unrelated donor; mm, mismatched unrelated donor; SIB, HLA-identical siblings; SYN, syngeneic.
Conditioning. BuCy indicates busulphane (oral application); Busilvex, soluble busulphane (intravenous); BuCy2, busulphane (intravenous); Cy, cyclophosphamide; TBI, total body irradiation (12 Gy); TBI8, TBI at 8 Gy; RIT, radio-immunotherapy; TLI, total lymphnode irradiation; FLAMSA: fludarabine, cytarabine, amsacrine, TBI (4 Gy), cyclophosphamide, ATG: antithymocyte globuline (Fresenius); alemtuzumab, antilymphoid antibody; Thymoglobulin, antithymocyte globulin (Genzyme); Flu, fludarabine; Melph, melphalan; Fara, fludarabine, cytarabine; CVB, cyclophosphamide, etoposide, carmustine; FBM, fludarabine, carmustine, melphalan; HAM, cytarabine, mitoxantrone; VP16, oral etoposide; Flag-Ida, fludarabine; cytarabine, granulocyte stimulating factor and idarubicine.
Cell source: BM. Indicates bone marrow, PBSC, peripherial blood stem cells.
GvHD D indicates time of clinical diagnosis of aGvHD in days after HSCT.
GvHD_grade indicates maximal grade of GvHD developed within the study.
- Table S2. Summary of the data and data sets used for multivariate analysis (XLS, 17.5 KB)
- Table S3. Classification factors F obtained for each of the 667 patient samples of the blinded set (Table 1) the GvHD specific pattern (Table 2) (XLS, 67.5 KB)
-
Column 1 gives a unique sample identifier (sample_ID), column 2 a unique patient identifier (patient_ID) (Table S1). Column 3 lists the obtained classification factors F of the aGvHD specific pattern. Column 4 depicts the time point of the urine sampling in days after HSCT and column 5 the clinical diagnosis at the same time point, 1 mean aGvHD diagnosed, 0 not. The 64 samples excluded from blinded assessment are indicated by *.
- Table S4. List of all 2,015 different polypeptides (protein_ID) detected, their calibrated molecular mass (Da), and normalized CE migration time (XLS, 235 KB)
- Table S5. Patients’ raw data, part 1 (XLS, 3.26 MB)
-
Tables S5-S8, in pivot format, show the CE-MS data of the 797 samples used in the study. Only data that were actually utilized (that are present in at least 40% of the samples of one of the diagnostic groups, see “Materials and Methods”) are shown. The protein IDs of all polypeptides are given in the first column named “protein_ID”, the unique sample_IDs constitute the first row. The MS data from each sample are reflected in one column. The number in each cell represents the calibrated amplitude of the mass spectrometric signal of each polypeptide detected in the sample.
- Table S6. Patients’ raw data, part 2 (XLS, 7.64 MB)
- Table S7. Patients’ raw data, part 3 (XLS, 7.39 MB)
- Table S8. Patients’ raw data, part 4 (XLS, 7.36 MB)
|
|
